Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis
Status:
Recruiting
Trial end date:
2024-04-22
Target enrollment:
Participant gender:
Summary
The present study (D5272C00001/Legacy #3151-201-008) aims to evaluate the efficacy and safety
of brazikumab in patients with moderately to severely active UC and will include assessments
of clinical responses as demonstrated by improvement of symptoms and of colonic mucosal
appearance as observed on endoscopy.